DiaSorin (DIA IM) 9M 2026 (EUR): Revenue 910mln; Adj. EBITDA 297mln; Adj. EBIT 228mln; Adj. net income 159mln; Q3 revenue +8% at constant FX; 2026 guidance confirmed, including Adj. EBITDA margin 32-33%

DiaSorin (DIA IM) 9M 2026 (EUR): Revenue 910mln; Adj. EBITDA 297mln; Adj. EBIT 228mln; Adj. net income 159mln; Q3 revenue +8% at constant FX; 2026 guidance confirmed, including Adj. EBITDA margin 32-33%.

A nine-month print with guidance reaffirmed is typically a low-drama event for mid-cap European healthcare; the market's focus on such releases tends to settle on whether the confirmed range was ever genuinely in doubt, and a reiterated margin band after three quarters usually signals the year is tracking close to internal plan. The detail that tends to matter most in diagnostics is the split between the core immunoassay and molecular franchises and the growth at constant FX, since reported figures in this sector are routinely distorted by currency translation and by the wind-down of pandemic-era testing revenue; an organic constant-FX growth rate is the cleaner read on underlying instrument placement and reagent pull-through. Confirmed EBITDA margin guidance carries weight because margin, not revenue, has historically been the swing factor for this peer set, sensitive to product mix, instrument depreciation and any residual contribution from COVID-related lines. The follow-ons are the usual ones: management commentary on installed-base momentum and assay menu expansion, any colour on pricing and hospital procurement in key geographies, and whether peers reporting around the same window corroborate the demand picture. As a reaffirmation rather than a raise, precedent suggests the stock reaction hinges on positioning into the print rather than on the headline itself.